EGFR and non-small cell lung carcinoma: Amivantamab monotherapy demonstrated an ORR of 40% (95% CI: 29-51) and a median PFS of 8.3 months (95% CI: 6.5-10.9) in the open-label CHRYSALIS study.40 In comparison, a real-world analysis of patients with EGFR Ex20ins-mutated NSCLC demonstrated a 14% ORR and a median PFS of 3.3 months across second-line treatments after platinum chemotherapy.41